Trial Details
Not RecruitingBasic Information
| Clinical ID | c5685 |
|---|---|
| Identifier | NL-OMON55161 |
| Trial Title | A PHASE I, RANDOMIZED, DOUBLE BLINDED, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE AND MULTIPLE ASCENDING DOSES OF ORAL GDC-8264 AND THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF GDC-8264 IN HEALTHY VOLUN |
| Trial URL | Visit Original Page |
Study Information
| Study Results | Yes |
|---|---|
| Conditions | Inflammatory Bowel Disease irritable bowel syndrome;10017969;10003816 |
| Interventions | The subjects will receive a single or multiple doses of GDC-8264 or placebo as tablets orally with 240 milliliters (mL) of water, or as a suspension. The starting dose is 5 mg. Midazolam is given through a syringe without a needle in th |
Participant Information
| Sponsor | Genentech, Inc. |
|---|---|
| City | NULL |
| Country/Region | Netherlands |
Enrollment Criteria
| Sex Requirement | NOT SPECIFIED |
|---|---|
| Age Requirement | ADULT |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | NULL |
Time Information
| Start Date | NULL |
|---|---|
| Primary Completion Date | NULL |
| Completion Date | NULL |